
ParcelBio
ParcelBio is a YC Winter 2024 (W24) company. Team of 5.
About ParcelBio
Summary
ParcelBio develops APEXm, an engineered mRNA platform that produces higher peak protein expression and sustains it longer than conventional mRNA, hitting therapeutic thresholds that standard RNA technologies cannot reach. The platform uses proprietary RNA domains to recruit the cell's native stabilizing machinery, making it modular across any encoded protein and any target cell type. Lead programs focus on in vivo CAR-T for autoimmune disease and oncology, replacing approaches limited by insufficient potency or durability.
From the Y Combinator listing
Next-generation mRNA medicines
ParcelBio is delivering the next generation of RNA medicines.
Facts
- Healthcare / Healthcare -> Therapeutics
- 5
- Active
- Early
Founders (2)
- Chris Carlson
- David Weinberg
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works